The addition of radiation to chemotherapy did not improve overall survival in patients with locally advanced endometrial ...

在全球范围内，子宫内膜癌（Endometrial Cancer，EC）成为发达国家最常见的妇科恶性肿瘤之一，其发病率正持续攀升，严重威胁着女性健康。尽管早期EC患者经过手术治疗后的5年生存率可高达80%至90%，但若肿瘤扩散至局部或远处，其生存率会骤降至68%及17%。为了改善这一状况，迫切需要探索新的诊疗策略。

The EC has approved GSK's Jemperli (dostarlimab) combined with chemotherapy for primary advanced or recurrent endometrial ...

Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...